Cleveland Clinic has entered into a strategic partnership with bioanalytics company Aspira Women’s Health on efforts to improve artificial intelligence-powered diagnostics for women’s health.
The two organizations will collaborate on research projects aimed at discovering and validating biomarker signatures, as well as developing analytical models that improve diagnostic accuracy, clinical utility, and patient care.
The agreement also includes a framework for future expansion in terms of data generation, translational development and clinical research efforts, according to the announcement.
Through this partnership, both organizations aim to expand access to patient samples, strengthen clinical validation capabilities, and help accelerate the development and commercialization of multi-ohm diagnostics for women’s health.
The collaboration will be co-led by Kevin Elias, MD, and Todd Pappas, MD, of the Cleveland Clinic. The research is carried out in collaboration with the multidisciplinary research team at Aspira Women’s Health.
Elias said in a statement that the organizations believe the integration of multigenic biomarkers and advanced AI-driven analysis “represents a very promising frontier in precision diagnostics.”
“We have already demonstrated that this approach has the potential to improve the diagnosis of ovarian cancer, and we believe it can be applied more broadly across women’s health,” Elias said. “This collaboration brings together complementary scientific, clinical, translational and commercial expertise with the common goal of advancing more accurate non-invasive tools that can meaningfully improve patient care and clinical decision-making.”
